欧盟委员会批准辉瑞的 PREVENAR 20® 以帮助保护婴儿和儿童。 European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children.
欧盟委员会已授予辉瑞公司的 20 价肺炎球菌结合疫苗 (PREVENAR 20) 上市许可，以保护 6 周至 18 岁以下的婴儿和儿童免受肺炎链球菌引起的肺炎、侵袭性疾病和急性中耳炎的侵害。 The European Commission has granted marketing authorization for Pfizer's 20-valent pneumococcal conjugate vaccine (PREVENAR 20) to protect infants and children from 6 weeks to less than 18 years against pneumonia, invasive disease, and acute otitis media caused by Streptococcus pneumoniae. 该疫苗提供最广泛的血清型覆盖范围，已获准在所有 27 个欧盟成员国以及冰岛、列支敦士登和挪威使用。 The vaccine, which offers the broadest serotype coverage, has been approved for use across all 27 EU member states, as well as Iceland, Lichtenstein, and Norway.